An assessment of sequential measurements of immune complex levels in ovarian cancer patients with respect to clinical progress.
An evaluation of immune-complex levels as an additional parameter in the clinical follow-up of ovarian cancer patients is described. These patients were treated aggressively with monthly chemotherapy following surgery. Sequential measurements of immune-complex levels have been carried out concurrently and clinical findings were recorded in a uniform manner suitable for comparison with the levels of immune complexes. The relationships between changes in tumor mass and changes in levels of immune complexes were investigated. A significant relationship between decreasing immune-complex levels and simultaneously decreasing tumor mass was found. Chemotherapy was associated with a decrease in immune-complex levels which increased again within 1 month. These data did not support an effective role for immune-complex levels in the evaluation of these patients.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000276:immunology / Q000601:surgery; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy / Q000276:immunology / Q000601:surgery; D000936:Antigen-Antibody Complex / Q000032:analysis*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002291:Carcinoma, Papillary / Q000188:drug therapy / Q000276:immunology / Q000601:surgery; D004715:Endometriosis / Q000188:drug therapy / Q000276:immunology / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000601:surgery
D000936:Antigen-Antibody Complex; D000970:Antineoplastic Agents